Artemisinin -based Combination

Malaria Artemisinin-based Combination Therapy Overview Successful malaria control depends greatly on treatment with efficacious anti-malarial drugs. Countries have a National Malaria Treatment Policy, that specifies drugs for treatment of both uncomplicated and severe malaria, malaria in pregnancy and what to do if first line treatment fails. As drug resistance develops to existing drugs, new ones need to be introduced. For plasmodium falciparum use of two or more drugs with different modes of action in combination is now recommended to provide adequate cure rate and delay development of resistance. Currently artemisinin-based combination therapy (ACT) is recommended for the treatment of P. falciparum malaria. Fast acting artemisinin-based compounds are combined with a drug from a different class. Companion drugs include lumefantrine, mefloquine, amodiaquine, sulfadoxine/pyrimethamine, piperaquine and chlorproguanil/dapsone. Artemisinin derivatives include dihydroartemisinin, artesunate and artemether. Implementation of the recommendation to use ACTs is limited by the small number of available and affordable co-formulated anti-malarial drugs, but most countries are now starting to implement this regimen. A co-formulated drug is one, in which two different drugs are combined in one tablet; this is important to ensure both drugs are used. Artemether/lumefantrine was the first fixed-dose artemisinin-based combination therapy recommended and pre-qualified by WHO for the treatment of uncomplicated malaria caused by P. falciparum. It has been shown to be effective both in sub- Saharan Africa and in areas with multi-drug resistant P. falciparum in Southeast Asia. It is currently recommended as first-line treatment for uncomplicated malaria in several countries. However, its complex treatment regimen of two doses daily for three days could affect adherence. A fixed-dose combination of amodiaquine-artesunate was launched in February 2007. The benefits of ACTs are their high efficacy, fast action and the reduced likelihood of resistance developing. In order to make best use of them, it is critical to address issues of delivery, access and cost. Chloroquine is still the first line treatment for P.vivax and P. ovale, while primaquine can be used to treat liver stage parasites of P.vivax, in areas of low transmission if adherence is guaranteed.